Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

GSK plc ADR Stock

Price
Target price
€50.50

€50.50

1.210%
0.6
1.210%
-

-

 
Buy 1 Sell 3
Buy 1
Sell 3
27.02.26 / Tradegate WKN: A3DMHS / Symbol: GSK / Name: GSK / Stock / Pharmaceuticals / Large Cap /
Latest predictions
20.02.26
-2.97%
sell
14.01.26
13.43%
sell
06.01.26
16.36%
sell
03.08.25
55.86%
buy
Show more
Best running prediction
-
03.08.25
55.86%
buy
Your prediction
Pros and Cons of GSK plc ADR in the next few years
Wizard

GSK plc ADR Stock

There is an upward development for GSK plc ADR compared to yesterday, with an increase of €0.60 (1.210%).
So far the community has only identified positive things for GSK plc ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
What does GSK do?

Pros and Cons of GSK plc ADR in the next few years

Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of GSK plc ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
GSK plc ADR 1.210% -2.885% 19.104% 40.278% 20.813% 53.030% 44.286%
Bayer AG ADR -6.420% -12.069% -12.821% 83.784% 15.909% -31.544% -19.048%
UCB S.A. 1.010% -9.412% -3.976% 40.689% 5.813% 204.411% 206.117%
Teva Pharmaceutical Industries Ltd ADR -2.090% -1.375% 6.296% 82.803% 6.691% 207.281% 222.110%

Comments

GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
Ratings data for GSK provided by MarketBeat
Show more

Barclays PLC 
0
Report Share
20.02.26 Sell -2.97%

GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for GSK provided by MarketBeat
Show more

Morgan Stanley 
0
Report Share
14.01.26 Sell 13.43%

GSK (NYSE:GSK) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating.
Ratings data for GSK provided by MarketBeat
Show more

Barclays PLC 
0
Report Share
06.01.26 Sell 16.36%
Show more
Not a member yet? Sign up for free!

News

Why Rapt Therapeutics Stock Soared Today: https://g.foolcdn.com/editorial/images/852093/medical-researchers-gettyimages-675577941.jpg
Why Rapt Therapeutics Stock Soared Today

Shares of Rapt Therapeutics (NASDAQ: RAPT) surged on Tuesday after the immunology specialist struck a deal to be acquired by British pharmaceutical leader GSK (NYSE: GSK) for $2.2 billion.

By the

TheMotleyFool 
0 20.01.26
GSK Unveils Fast-Tracked IBP Transformation with OMP at Gartner Supply Chain Planning Summit
GSK Unveils Fast-Tracked IBP Transformation with OMP at Gartner Supply Chain Planning Summit

ANTWERPEN, BE / ACCESS Newswire / October 9, 2025 / OMP, a leader in supply chain planning solutions, is spotlighting at the Gartner Supply Chain Planning Summit 2025 in London how GSK is

irwpresse_en 
0 09.10.25